Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (AZNCF)
OTHER OTC:AZNCF
Holding AZNCF?
Track your performance easily
Earnings Data
Report Date
Feb 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
2.09Last Year’s EPS
1.45Same Quarter Last Year
Moderate Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: 8.21%
|Next Earnings Date:Jul 26, 2018
Earnings Call Sentiment|Positive
AstraZeneca reported strong revenue and EPS growth, driven by robust global demand and significant contributions from oncology and BioPharmaceuticals segments. However, challenges in the China market due to investigations and potential impacts from the IRA in the U.S. were noted as concerns.Company Guidance
In the recent Q3 call, AstraZeneca reported a 21% growth in total revenue, driven by strong global demand for their medicines, alongside a 27% increase in core EPS to $2.08. The year-to-date growth was also impressive, with revenue up by 19% and core EPS rising by 11%, despite a one-time $1.1 billion revenue boost in 2023. All therapy areas showed double-digit growth, contributing to an upgrade in the full-year guidance, now expecting high teens growth in both total revenue and core EPS. The company's global revenue distribution was highlighted, with 43% from the U.S., 21% from Europe, 13% from China, and an emerging market share of 14%, illustrating a strong performance outside China. AstraZeneca also announced a $3.5 billion investment in U.S. manufacturing and R&D, underlining the importance of the U.S. market. The company emphasized its focus on pipeline regeneration, aiming for $80 billion in total revenue by 2030 and a mid-30s percentage operating margin by 2026.Strong Revenue and EPS Growth
In the third quarter, total revenue grew by 21%, driven by robust global demand for AstraZeneca's medicines. Core EPS increased by 27% to $2.08.
Upgraded Full Year Guidance
AstraZeneca upgraded its full year guidance, now expecting both total revenue and core EPS to increase by high teens percentages.
Emerging Markets Growth
AstraZeneca reported 30% revenue growth in emerging markets outside of China for the year-to-date.
Oncology Segment Performance
Oncology total revenues grew 22% to $16 billion in the first nine months, with strong demand in the U.S., Europe, and emerging markets.
BioPharmaceuticals Growth
BioPharmaceuticals medicines delivered total revenue of $15.9 billion in the first nine months, representing growth of 20%.
Rare Disease Segment Growth
Rare disease segment grew 14% to $6.4 billion in the first nine months, driven by neurology indications and increased patient demand.
---
AZNCF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AZNCF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $126.80 | $128.41 | +1.27% |
| Jul 25, 2024 | $156.26 | $154.51 | -1.13% |
| Apr 25, 2024 | $134.50 | $145.14 | +7.91% |
| Feb 08, 2024 | $130.45 | $122.29 | -6.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does AstraZeneca PLC (AZNCF) report earnings?
AstraZeneca PLC (AZNCF) is schdueled to report earning on Feb 06, 2025, TBA Not Confirmed.
What is AstraZeneca PLC (AZNCF) earnings time?
AstraZeneca PLC (AZNCF) earnings time is at Feb 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AZNCF EPS forecast?
AZNCF EPS forecast for the fiscal quarter 2024 (Q4) is 2.09.
---